Year: 2023

The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (Nasdaq: CBIO) (“Catalyst”) today announced completion of the business combination with GNI Group Ltd. and related entities. Catalyst received stockholder approval for all proposals necessary to complete the business combination at a special meeting of stockholders held on August 29, 2023. Catalyst effected a name change and a reverse stock split of Catalyst’s common stock immediately prior to the closing of the business combination. The combined company will operate under the name “Gyre Therapeutics, Inc.” (“Gyre”). As a result of the business combination, Beijing Continent Pharmaceuticals Co.,...

PRESS RELEASE – REGULATED INFORMATION Notification of transactions in shares by persons discharging managerial responsibility (“PDMRs”) Cambridge (UK) 30 October 2023: The Company makes the following announcement and notification in respect of the EU Market Abuse Regulation.1 Details of the person discharging managerial responsibilities / person closely associateda) Name Michael Rottenborn2 Reason for the notificationa) Position/status CEOb) Initial notification/Amendment Initial notification3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora) Name Hybrid Software Group PLCb) LEI 213800ZFW446QIHAB6544 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and...

MCLEAN, Va., Oct. 30, 2023 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Mission Technologies division was awarded a $79 million contract to support the Missile Defense Agency’s (MDA) mission to develop, test and field a missile defense system that will protect the U.S. and its allies against enemy ballistic missile attacks. The HII-led team will support MDA leadership on strategic, technical, programmatic, operational, policy and organizational matters regarding the integrated, layered missile defense system. The team will also provide engineering and technical support; management and professional services; and studies, analyses and evaluations. “We have assembled a highly experienced team that is committed to supporting the MDA in its important mission to defend the U.S. and its allies against a complex missile...

TORTOLA, British Virgin Islands, Oct. 30, 2023 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company” and includes PanAfrican Energy Tanzania Limited (“PAET”) and its other subsidiaries, and affiliates) (TSX-V: ORC.A, ORC.B) today announces an operational update. All amounts are in United States dollars (“$”) unless otherwise stated. OPERATIONAL Production, Sales and DemandGross conventional natural gas production, including fuel gas, was in line with forecasts and averaged 124.8 million cubic feet per day (“MMcfd”) for Q3 2023, of which 82.9 MMcfd was Additional Gas (“AG”). Gas deliveries decreased by 2% for Q3 2023 compared to Q2 2023 and increased by 4% for the nine months ended September 30, 2023 compared to the same prior year period. The decrease for Q3 2023 was primarily due to declining production from the...

Amsterdam, 30 October 2023 – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, today announces that VEON Ltd. and VEON Holdings B.V. have filed two motions with the relevant Kyiv district court, challenging the freezing of the corporate rights in Kyivstar, which was initially announced on the website of the Security Services of Ukraine (SSU) on 6 October 2023. Noting that corporate rights in Kyivstar belong exclusively to VEON, and that their full or partial seizure directly violates the rights of VEON and its international debt and equity investors, VEON requested the lifting of the freezing of its corporate rights in Kyivstar. In its filings, the Company also reiterated that any action aimed at the rights, benefits or funds of sanctioned individuals...

TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that as a result of its 1-for-17 reverse stock split of its common stock that became effective at 8:03 a.m. Eastern Time on October 30, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market on October 31, 2023. PaxMedica’s common stock will continue to trade under the existing trading symbol “PXMD.” The new CUSIP number for the common stock following the reverse stock split is 70424C 203. As a result of the reverse stock split, each 17 pre-split shares...

October 30, 2023 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMFDate Shares* Voting rightstheoretical** exercisable***30 September 2023 43,203,225 48,691,525 48,653,706*This number is calculated taking into account the cancellation, as at 30 September 2023, of 1,050,000 treasury shares purchased by the Company between 10 January and 8 September 2023 as part of the implementation of its shares buyback program, this cancellation having been acknowledged by decisions of the Chief Executive Officer of the Company dated 30 September 2023, upon delegation given by the Board of Directors pursuant to its meeting dated 25 July 2023, which decided to reduce the share capital by cancelling...

Ress Life Investments A/SNybrogade 12DK-1203 Copenhagen KDenmarkCVR nr. 33593163www.resslifeinvestments.com To: Nasdaq CopenhagenDate: 30 October 2023 Corporate Announcement 33/2023 Ress Life Investments A/S appoints Ketil Petersen as Chief Executive Officer Ress Life Investments A/S (“Ress Life”) announces that Ketil Petersen has been appointed new Chief Executive Officer (“CEO”) of Ress Life with effect from 15 November 2023. In this connection, Ketil Petersen will resign as member of the board of directors of Ress Life. Michael Ekmann resigns as CEO of Ress Life with effect from 30 April 2024. Ketil Petersen has more than 30 years of experience from the financial services industry in the Nordic region, and has held positions in Schroder Asset Management, BG Asset Management and Alm. Brand. Questions related to this announcement...

TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to provide the following update on Psyence Production. Psyence Production is a division of Psyence that oversees its psilocybin cultivation and production facility. Psyence operates one of the first government licensed commercial psilocybin production facilities in the world. Its cultivation and production facility, located in Southern Africa, is ISO22000 certified. Psyence is licensed to cultivate and export nature-derived psilocybin mushrooms for the legal, global medical market and commercial medical research market. Extraction capability expanded Psyence recently designed a new laboratory at the facility...

A Press Release which comprises the Results of the Early Exercsie of GIG Warrants is attached hereto. Attachment20231030 GIG – Press Release Results Final